Bleichmar Fonti & Auld LLP opened a securities fraud investigation into IBM after shares plunged more than 25 percent on July 14, when the company blamed a shortfall in its IBM Z mainframe business for a disappointing second quarter. The firm is examining whether IBM misrepresented its deal pipeline and IBM Z product outlook to investors.
A leading securities law firm has opened a fraud investigation into IBM, two months after the technology giant's shares lost a quarter of their value on weak mainframe sales.
Bleichmar Fonti & Auld LLP said it is examining whether IBM misrepresented "the pace of securing new business deals and the strength of its IBM Z outlook" in statements to investors. The firm's probe follows a July 14 earnings report in which IBM disclosed a "shortfall in our Z performance and the associated software stack, primarily in Transaction Processing."
IBM acknowledged it "faltered" and "did not adapt and move quickly enough," with "numerous large deals failed to close on the timelines we expected, driving the majority of our shortfall." The stock fell more than $75 in intraday trading that day, a decline exceeding 25 percent.
IBM Z is the company's mainframe platform, used for AI acceleration, multi-model AI capabilities, end-to-end encryption workloads, and ultra-high-throughput transaction processing. The platform anchors IBM's hybrid cloud strategy and generates recurring software and services revenue tied to mainframe hardware refresh cycles. A slowdown in Z sales points to potential weakness in enterprise hardware demand or competitive pressures from cloud-based alternatives offered by Amazon Web Services, Microsoft Azure, and Google Cloud.
BFA Law has recovered over $900 million in value from Tesla's board of directors and $420 million from Teva Pharmaceutical Industries. The firm is representing IBM investors on a contingency fee basis and encourages affected shareholders to submit their information through its website or contact Adam McCall at 212.789.3619.
Investors who purchased IBM shares and suffered losses may have legal options. The investigation could escalate into a securities class action if evidence of misrepresentation emerges. IBM's next earnings report will be closely watched for further disclosure on the Z product pipeline and deal closure rates, which will determine whether the company can restore investor confidence in its core infrastructure franchise.
This article is for informational purposes only and does not constitute investment advice.
